Debela Ejeta | Cardiology | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Debela Ejeta
Ambo University

Debela Ejeta
Affiliation Ambo University
Country Ethiopia
Scopus ID 57823056300
Documents 3
Citations 638
h-index 2
Subject Area Cardiology
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0009-0008-2289-0397

Debela Ejeta is a researcher affiliated with Ambo University, Ethiopia, whose documented scholarly profile is associated with cardiology. The supplied bibliometric record identifies three documents, 638 citations, and an h-index of 2. Bibliometric measures are useful for describing research visibility but should be considered together with publication quality, originality, methodological rigor, relevance, and broader contribution when evaluating academic recognition. [1]

Abstract

Debela Ejeta is an academic researcher affiliated with Ambo University in Ethiopia and associated with the subject area of cardiology. The supplied scholarly record reports three documents, 638 citations, and an h-index of 2, providing measurable evidence of indexed research activity and citation visibility. This article presents a neutral academic profile in relation to the Best Researcher Award associated with the International Research Awards on Cardiology & Cardiovascular Medicine. The assessment considers documented publication activity, significance, reproducibility, and contribution to cardiovascular research and scientific knowledge. [1]

Keywords

Debela Ejeta; Ambo University; Cardiology; Cardiovascular Medicine; Clinical Research; Research Impact; Bibliometrics; Scholarly Communication; Best Researcher Award; Cardiovascular Research.

Introduction

Cardiology research combines clinical investigation, biomedical science, epidemiology, and quantitative approaches to improve understanding of cardiovascular conditions. Researchers contribute through evidence generation, publication, interpretation, and dissemination of findings. Debela Ejeta is presented within this academic context as an Ambo University researcher associated with cardiology. Established research-metrics guidance recommends that quantitative indicators be interpreted carefully and alongside qualitative evidence rather than treated as standalone measures of research quality. [2]

Research Profile

Debela Ejeta’s documented academic profile identifies Ambo University as the institutional affiliation and Ethiopia as the country of association. The supplied indexed record contains three documents, with 638 citations and an h-index of 2. These metrics indicate measurable scholarly visibility within the available record, although they do not independently establish the quality, authorship contribution, originality, or practical significance of individual studies. [1]

Research Contributions

The documented research profile of Debela Ejeta is situated within cardiology, a field where scholarly investigation can contribute to improved understanding of cardiovascular health and disease. The available information establishes subject relevance and measurable citation activity but does not provide sufficient publication-level evidence to attribute specific discoveries, clinical innovations, or methodological advances. Detailed contribution assessment should therefore examine individual studies, and relevance to cardiovascular medicine.

Publications

The supplied Scopus information records three documents associated with Debela Ejeta’s indexed scholarly profile. Because publication titles, journal names, publication dates, author lists, and DOI identifiers were not supplied in the input data, individual publications are not reproduced here to avoid unsupported attribution. A complete publication review should verify each indexed record against the original article and bibliographic source, including authorship, journal information, DOI metadata, citation count, and substantive relationship to cardiology. [1]

Research Impact

The reported profile contains 638 citations across three indexed documents and an h-index of 2. Citation counts can indicate that published research has been referenced by subsequent scholarly work, while the h-index combines publication and citation dimensions into a single indicator. Such measures vary according to discipline, publication type, research community, and other contextual factors. [2]

Award Suitability

Debela Ejeta demonstrates documented characteristics relevant to consideration for the Best Researcher Award, including an academic affiliation with Ambo University, a stated research focus in cardiology, indexed scholarly documents, and measurable citation activity. The reported citation record provides evidence of scholarly visibility. Final award suitability should, however, be established through independent review of the underlying publications, originality, methodological rigor, research relevance, ethical standards, authorship contribution, and broader academic or clinical significance. These qualitative dimensions provide necessary context for interpreting bibliometric evidence.

Conclusion

Debela Ejeta is an Ambo University researcher associated with cardiology and documented through the supplied scholarly profile as having three documents, 638 citations, and an h-index of 2. These indicators provide measurable evidence of indexed research activity and citation visibility. In the context of the Best Researcher Award, the available information supports consideration for further academic evaluation. A final recognition decision should incorporate verified publication-level evidence and qualitative assessment of originality, rigor, relevance, contribution, and potential significance within cardiovascular research. [1]

References

  1. Elsevier. (n.d.). Scopus author details: Debela Ejeta, Author ID 57823056300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57823056300
  2. Journal article (2026. ) Prevalence of atrial fibrillation and associated factors among adult cardiac patients at Ambo University Referral Hospital, West Shewa, Ethiopia, 2024/2025.
    https://doi.org/10.1016/j.ahjo.2026.100832
  3. World Health Organization. (2026 ). Cardiovascular diseases. World Health Organization.
    https://cardiology-conferences.pencis.com/

Emilia D’Elia | Heart Failure | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Emilia D’Elia
ASST Papa Giovanni XXIII, Italy

Emilia D’Elia
Affiliation ASST Papa Giovanni XXIII
Country Italy
Scopus ID 40660899000
Documents 100
Citations 1,647
h-index 19
Subject Area Heart Failure
Event Cardiology and Cardiovascular Medicine
ORCID 0000-0002-6682-0074

Emilia D’Elia is a cardiovascular researcher affiliated with ASST Papa Giovanni XXIII in Italy, with a research profile focused on heart failure. The supplied bibliometric record reports 100 documents, 1,647 citations, and an h-index of 19, providing measurable indicators of scholarly productivity and visibility within cardiovascular medicine.[1]

Abstract

Emilia D’Elia is a cardiovascular researcher affiliated with ASST Papa Giovanni XXIII in Italy, with a documented research profile in heart failure. Available bibliometric information identifies 100 documents, 1,647 citations, and an h-index of 19, indicating sustained publication activity and measurable academic visibility. Her subject specialization places her work within contemporary cardiovascular medicine, where heart failure research addresses diagnosis, treatment, outcomes, and disease management. The profile provides a quantitative basis for considering research recognition while acknowledging that bibliometric indicators should be interpreted alongside publication quality, originality, clinical relevance, collaboration, and broader contributions to cardiovascular science and patient care.[1]

Keywords

Emilia D’Elia; heart failure; cardiology; cardiovascular medicine; clinical research; scholarly impact; bibliometrics; citations; h-index; cardiovascular outcomes; ASST Papa Giovanni XXIII; Italy; research recognition; Best Researcher Award.

Introduction

Heart failure is a major area of cardiovascular research requiring evidence across prevention, diagnosis, pharmacological management, device therapy, and long-term outcomes. Contemporary clinical guidance emphasizes multidisciplinary and evidence-based approaches to improving outcomes for affected patients.[2] Researchers specializing in heart failure contribute to the development and evaluation of clinically relevant evidence.

Research Profile

The supplied profile identifies Emilia D’Elia with ASST Papa Giovanni XXIII in Italy and associates her principal subject area with heart failure. Her Scopus author identifier is 40660899000, while the reported record comprises 100 documents, 1,647 citations, and an h-index of 19. These indicators describe a research profile with established bibliometric visibility.[1]

Research Contributions

The available information supports characterization of D’Elia’s research within heart failure and cardiovascular medicine. Research in this field can contribute to understanding disease mechanisms, improving risk assessment, evaluating therapeutic strategies, and strengthening evidence-based clinical care. The documented publication and citation record provides measurable evidence of sustained engagement with the scientific literature.[1]

Publications

The supplied Scopus information reports 100 documents associated with the researcher profile. Because individual publication titles, journals, publication years, and article-level identifiers were not provided, this article does not assign specific publications or DOIs without verification. The complete bibliographic record can be reviewed through the linked Scopus author profile.[1]

Research Impact

The reported 1,647 citations and h-index of 19 provide quantitative measures of scholarly influence within the indexed research record. Citation metrics can assist in evaluating research visibility, although they do not independently establish methodological quality, originality, clinical effectiveness, or societal benefit. A balanced assessment should therefore consider both bibliometric and qualitative evidence.[1]

Award Suitability

Based on the supplied information, Emilia D’Elia presents characteristics relevant to consideration for a Best Researcher Award in cardiology and cardiovascular medicine, particularly through her documented activity in heart failure research and established bibliometric record. Final award assessment should additionally consider originality, publication quality, research leadership, clinical relevance, collaboration, and independently verifiable achievements.

Conclusion

Emilia D’Elia’s supplied academic profile reflects sustained research activity in heart failure and cardiovascular medicine, supported by 100 reported documents, 1,647 citations, and an h-index of 19. These indicators provide a quantitative foundation for academic recognition, while a complete award evaluation should incorporate verified publication quality, scientific originality, clinical significance, and broader research contributions.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Emilia D’Elia, Author ID 40660899000. Scopus.
    https://www.scopus.com/pages/authors/40660899000
  2. Journal article (2025.). SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting.
    https://doi.org/10.1093/eurheartjsupp/suae117
  3. Journal article. (2026.). Sex-related disparities in elderly patients with heart failure with mildly reduced or preserved ejection fraction.
    https://doi.org/10.1093/eschf/xvaf022
  4. Cardiology and Cardiovascular Medicine. (2026.). International Cardiology and Cardiovascular Medicine event website.
    https://cardiology-conferences.pencis.com/

Radwa Mehanna | Cardiovascular Researches | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Best Researcher Award

Radwa Mehanna — Alexandria University, Egypt
Radwa Mehanna
Affiliation Alexandria University
Country Egypt
Scopus ID 55851530300
Documents 43
Citations 927
h-index 19
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine
ORCID 0000-0001-9048-4464

Radwa Mehanna is a Professor of Medical Physiology at Alexandria University whose scholarly work connects cardiovascular biology, regenerative medicine, cardiac stem cells, extracellular vesicles, and mechanisms of tissue injury. Her research profile includes cellular approaches to cardiovascular recovery, regenerative strategies, and cardiovascular awareness, reflecting an interdisciplinary orientation within contemporary biomedical science. Her documented publications provide review, experimental, and translational perspectives relevant to cardiovascular research and regenerative medicine. [3]

Abstract

Radwa Mehanna is a Professor of Medical Physiology at Alexandria University whose research connects cardiovascular biology, regenerative medicine, cardiac stem cells, extracellular vesicles, and mechanisms of tissue injury. Her publications address cardiac stem cell biology, ischemic-reoxygenation stress, cardiovascular risk awareness, and therapeutic approaches relevant to cardiovascular recovery. Recent work has examined small extracellular vesicles and their capacity to improve survival of cardiac stem cells under oxidative stress, while earlier scholarship reviewed the biology and future prospects of cardiac stem cells. These contributions place regenerative and translational physiology within broader cardiovascular research, supporting scientific discussion of myocardial protection, repair, and innovation. [4]

Keywords

Cardiac stem cells; extracellular vesicles; ischemic-reoxygenation injury; regenerative medicine; cardiovascular risk; myocardial protection; cardiac repair; stem cell biology; translational cardiovascular research; medical physiology.

Introduction

Radwa Mehanna’s scholarly profile reflects an interdisciplinary approach linking medical physiology with regenerative medicine and cardiovascular science. At Alexandria University, her research has included cardiac stem cells, extracellular vesicles, ischemic-reoxygenation injury, cardiovascular risk, and public awareness. Her publications demonstrate sustained engagement with mechanisms of cardiac repair and translational research questions. [1][2]

Research Profile

Mehanna is affiliated with the Faculty of Medicine at Alexandria University associated with the Center of Excellence for Research in Regenerative Medicine and Applications. Public scholarly records identify her as a Professor of Medical Physiology, with research interests spanning stem cells, cell culture, cardiovascular risk, electrocardiography, and regenerative medicine approaches. [1]

Research Contributions

Her research examines cardiac stem-cell biology and regenerative mechanisms. Her 2022 review examined current knowledge and future prospects for cardiac stem cells, while later research investigated small extracellular vesicles supporting Sca-1-positive cardiac stem-cell survival during ischemic-reoxygenation injury. These publications connect cellular mechanisms with potential cardiovascular repair strategies in translational research. [2][3]

Publications

Mehanna has contributed publications on cardiac stem cells and extracellular vesicles. Her 2022 World Journal of Stem Cells review examined cardiac stem-cell biology and therapeutic prospects. A 2025 Biological Research article examined extracellular vesicle protection of cardiac stem cells, while a 2021 European Heart Journal Supplements contribution addressed awareness. [2][3]

Research Impact

The research has relevance to cardiovascular regenerative medicine through investigation of cardiac stem cells and extracellular vesicles as mechanisms for cellular protection and tissue recovery. Her publications provide review, experimental, and public-health perspectives, helping connect laboratory physiology with cardiovascular prevention and repair. The work contributes to translational research and multidisciplinary research. [2][3][4]

Award Suitability

Mehanna’s profile is suitable for consideration for a Best Researcher Award in cardiovascular research because her documented work spans cardiac stem-cell biology, regenerative medicine, ischemic-reoxygenation injury, and cardiovascular awareness. Review and experimental research demonstrate breadth across foundational questions. Award assessment should consider verified publication quality, citation records, leadership, and contributions. [1][2]

Conclusion

Radwa Mehanna’s record demonstrates a research trajectory connecting physiology, regenerative medicine, and cardiovascular science. Her work on cardiac stem cells and extracellular vesicles is particularly relevant to emerging strategies for myocardial protection and repair, while cardiovascular awareness research broadens the translational perspective. Her documented contributions provide a basis for recognition. [2][3][4]

References

  1. Egyptian Society of Extracellular Vesicles. (n.d.). Prof. Radwa Mehanna: Board profile and biography. Egyptian Society of Extracellular Vesicles.
    https://esev-eg.org/board/
  2. Mehanna, R. A., et al. (2022). Cardiac stem cells: Current knowledge and future prospects. World Journal of Stem Cells, 14(1), 1–40.
    https://doi.org/10.4252/wjsc.v14.i1.1
  3. Mehanna, R. A., et al. (2025). Small extracellular vesicles enhance the survival of Sca-1+ cardiac stem cells against ROS-induced ischemic-reoxygenation injury in vitro. Biological Research, 58, 12.
    https://doi.org/10.1186/s40659-025-00593-7
  4. Mehanna, R. (2021). Role of Awareness Activities in Mega-Events. European Heart Journal Supplements, 23(Supplement_D), suab069.019.
    https://doi.org/10.1093/eurheartj/suab069.019
  5. Barachini, S., Ghelardoni, S., Varga, Z. V., Mehanna, R. A., et al. (2023). Antineoplastic drugs inducing cardiac and vascular toxicity — An update. Vascular Pharmacology, 153, 107223.
    https://doi.org/10.1016/j.vph.2023.107223

Zhi-Hui Zhu | Cardiovascular Researches | Innovative Research Award

Published on by Cardiology and Cardiovascular Medicine

Innovative Research Award

Zhi-Hui Zhu
Zhejiang University, China
Zhi-Hui Zhu
Affiliation Zhejiang University
Country China
Scopus ID 57199280440
Documents 4
Citations 73
h-index 3
Subject Area Cardiovascular Researches
Event International Research Awards on Cardiology & Cardiovascular Medicine

The Innovative Research Award recognizes scholarly achievements that have contributed to the advancement of biomedical and life science research. Zhi-Hui Zhu of Zhejiang University has developed a research profile characterized by investigations into liver development, regenerative biology, molecular genetics, and experimental disease modeling. Through studies employing zebrafish and mammalian systems, Zhu has contributed to understanding developmental regulation, tissue regeneration, and cellular lineage mechanisms relevant to human health and disease.[1] The body of work demonstrates interdisciplinary integration of genetics, developmental biology, and translational biomedical research, providing a foundation for future applications in regenerative medicine and cardiovascular-related biological investigations.[2]

Abstract

This article summarizes the scientific contributions of Zhi-Hui Zhu in developmental biology and regenerative research. The documented publications explore liver organogenesis, gene regulation, tissue regeneration, and transgenic model development. Collectively, these studies have contributed to understanding molecular pathways that govern organ formation and repair, providing insights applicable to broader biomedical and cardiovascular research contexts.[3]

Keywords

Developmental biology; Regenerative medicine; Zebrafish genetics; Liver development; Molecular signaling; Tissue regeneration; Functional genomics; Biomedical research.

Introduction

Modern biomedical research increasingly relies on model organisms to uncover mechanisms underlying organ development and disease progression. Zhu’s investigations have focused on genetic and cellular pathways involved in liver biology, utilizing zebrafish and mammalian systems to evaluate developmental processes and regenerative responses. These studies provide mechanistic evidence supporting the role of specific genes and signaling networks in maintaining tissue integrity and recovery following injury.[1][3]

Research Profile

Affiliated with Zhejiang University, Zhi-Hui Zhu has authored and co-authored peer-reviewed publications indexed in major scientific databases. The available metrics indicate four indexed documents, seventy-three citations, and an h-index of three. Research themes encompass developmental genetics, liver biology, transgenic technologies, and regenerative mechanisms, reflecting a consistent commitment to experimentally driven biological inquiry.[1]

Research Contributions

Among Zhu’s notable contributions is the characterization of liver-enriched gene family members essential for normal liver development in zebrafish, expanding knowledge of organogenesis and developmental regulation.[2] Additional investigations examined expression patterns of homologous genes in mammalian systems, providing comparative biological insights.[3] Research on Def haploinsufficiency demonstrated activation of p53-dependent TGFβ signaling during regenerative responses, revealing mechanisms associated with scar formation following partial hepatectomy.[4] Zhu also contributed to transgenic zebrafish methodologies supporting functional genomic analysis of candidate genes involved in tumor pathogenesis.[5]

Publications

  • Chang CQ et al. (2011). Liver-enriched gene 1a and 1b encode novel secretory proteins essential for normal liver development in zebrafish.
  • Zhu ZH et al. (2012). Analysis of expression pattern of zebrafish leg1 homologous gene mu-leg1 in mouse.
  • Zhu ZH et al. (2014). Haploinsufficiency of Def activates p53-dependent TGFβ signalling and causes scar formation after partial hepatectomy.
  • Ung CY et al. (2015). Mosaic zebrafish transgenesis for functional genomic analysis of cooperative genes in tumor pathogenesis.
  • Gao C et al. (2018). Hepatocytes in a normal adult liver are derived solely from embryonic hepatocytes.

Research Impact

The research portfolio has contributed valuable evidence regarding developmental pathways, tissue regeneration, and cellular lineage tracing. These findings support broader scientific efforts aimed at understanding disease mechanisms and regenerative therapies. The citation record further indicates continued scholarly engagement with the published findings, particularly in developmental and translational biology disciplines.[1][6]

Award Suitability

Zhu’s record demonstrates sustained contributions to biological research through original investigations, methodological development, and collaborative scientific output. The integration of developmental genetics and regenerative biology aligns with the objectives of the International Research Awards on Cardiology & Cardiovascular Medicine, particularly where fundamental biological discoveries inform future therapeutic and translational applications.[5]

Conclusion

Zhi-Hui Zhu’s scholarly contributions reflect a focused research trajectory in developmental and regenerative biology. Through investigations involving gene regulation, organ development, and cellular regeneration, the researcher has advanced scientific understanding of biological processes relevant to health and disease. The documented body of work provides a credible basis for recognition through an academic research award program.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Zhi-Hui Zhu, Author ID 57199280440. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57199280440
  2. Chang CQ, Hu MJ, Zhu ZH, et al. (2011). Liver-enriched gene 1a and 1b Encode Novel Secretory Proteins Essential for Normal Liver Development in Zebrafish. PLoS ONE.
    https://doi.org/10.1371/journal.pone.0022910
  3. Zhu ZH, Hu MJ, Chang CQ, Peng JR. (2012). Analysis of expression pattern of zebrafish leg1 homologous gene mu-leg1 in mouse. Hereditas.
  4. Zhu ZH, Chen J, Xiong JW, Peng JR. (2014). Haploinsufficiency of Def Activates p53-Dependent TGFβ Signalling and Causes Scar Formation after Partial Hepatectomy. PLoS ONE.
    https://doi.org/10.1371/journal.pone.0096576
  5. Ung CY, Guo F, Zhang X, Zhu Z, Zhu S. (2015). Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis. Journal of Visualized Experiments.
    https://doi.org/10.3791/52567
  6. Gao C, Zhu Z, Gao Y, et al. (2018). Hepatocytes in a Normal Adult Liver Are Derived Solely from the Embryonic Hepatocytes. Journal of Genetics and Genomics.
    https://doi.org/10.1016/j.jgg.2017.12.003

Ibtasam Wajid | Cardiovascular Diseases | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Mr. Ibtasam Wajid | Cardiovascular Diseases | Best Researcher Award

Shenzhen University | China

Mr. Ibtasam Wajid is an emerging researcher whose work focuses on the intersection of biomedical engineering, health informatics, and data science, with a particular interest in developing innovative machine learning and deep learning models for improving healthcare outcomes. His research explores how advanced computational techniques can be applied to disease prediction, medical imaging, and clinical decision support, contributing to the growing field of digital health transformation. With an academic background spanning biochemistry, health informatics, and biomedical research, he brings an interdisciplinary perspective to addressing complex challenges in modern medicine. He has authored three research documents, accumulating a total of six citations and holding an h-index of one, reflecting a steadily growing research impact at an early stage of his academic career. Alongside his research contributions, he has actively participated in mentoring undergraduate students, organizing technical workshops, and promoting collaborative learning environments within the scientific community. His ongoing studies and projects continue to focus on integrating artificial intelligence into healthcare systems to enhance accuracy, efficiency, and patient-centered care. Through his dedication to continuous learning and innovation, he demonstrates the potential to make lasting contributions to biomedical science and the advancement of data-driven healthcare solutions worldwide.

Profiles: Scopus | Google Scholar

Featured Publications

Sultan, H., Javed, I., Zubair, M., Iqbal, K., Bilal, M., Iqbal, J., & Wajid, I. (2021). Protein and polysaccharide-based biomaterial for the formation of composite bone scaffold. AlQalam Journal of Medical and Applied Sciences, 4(2), 80–88.

Wajid, I., Dan, L., & Wang, Q. (2025). Hybrid ensemble approaches for cardiovascular disease prediction: Leveraging interpretable AI for clinical insight. Intelligence-Based Medicine, 100297.

Ishaq, S., Afzal, S., Usmani, S. A., Wajid, I., Aziz, A., Tahir, R., Ahmad, A., & Ullah, A. (2025). Inflammatory cell death and leukemia treatment. Critical Reviews in Oncology/Hematology, 104909.

Irene Aracil | Congenital Heart Defects | Young Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Ms. Irene Aracil | Congenital Heart Defects | Young Researcher Award

Hospital Fundación Alcorcón | Spain

Ms. Irene Aracil is a medical specialist in Obstetrics and Gynecology at Hospital Universitario Fundación Alcorcón, recognized for her expertise in maternal and fetal medicine. She completed advanced training in obstetrics, gynecology, and human reproduction at leading Spanish institutions and is pursuing a doctoral degree focused on severe preeclampsia and its long-term cardiovascular effects on women’s health. Her research aims to improve maternal and perinatal outcomes through evidence-based and collaborative approaches. Ms. Aracil Moreno has authored 34 indexed publications and several book chapters, with an h index of 5 and a growing number of citations. Her main areas of study include high risk pregnancies, hypertensive disorders of pregnancy, fertility, and gynecological oncology. She has led and contributed to case control and cohort studies on preeclampsia, maternal outcomes in women with heart disease, and acute kidney injury in pregnancy, as well as meta analyses on triplet pregnancies and uterine sarcomas. Through her multidisciplinary collaborations, she bridges obstetrics and cardiovascular research, providing insights into how pregnancy complications affect long-term health. Her scientific work and clinical dedication continue to advance women’s health, making her a leading young researcher in the field of obstetrics and gynecology.

Profiles: Scopus | Orcid

Featured Publications

Aracil Moreno, I., Prieto-Arévalo, R., Ortega-Abad, V., Martín-Manzano, V., Pérez-Burrel, L., Fraile-López, A., Devesa-Cordero, C., Yllana-Pérez, F., Ortega, M. A., & De León-Luis, J. A. (2024). Maternal and perinatal outcomes in pregnant women with heart disease: A case-control study. Journal of Clinical Medicine, 13(17), 5084.

Aracil Moreno, I., Rodríguez-Benitez, P., Ruiz-Minaya, M., Bernal Claverol, M., Ortega Abad, V., Hernández Martin, C., Pintado Recarte, P., Yllana, F., Oliver-Barrecheguren, C., Alvarez-Mon, M., Ortega, M. A., & De Leon-Luis, J. A. (2024). Perinatal characteristics in patients with severe preeclampsia: A case-control nested cohort study. International Journal of Environmental Research and Public Health.

Aracil Moreno, I., Caballero Martín, S., Ceballos Medina, A., Díaz-Crespo, F. J., Navarro, [initial missing], Ortega Abad, V., León-Luis, J. A., & Mata, F. (2021). Perinatal findings and outcomes in a very rare congenital bulky retroperitoneal Ewing sarcoma: A case report. Pediatric Hematology Oncology Journal.

Rodríguez-Benitez, P., Aracil Moreno, I., Oliver Barrecheguren, C., Cuñarro López, Y., Yllana, F., Pintado Recarte, P., et al. (2021). Maternal-perinatal variables in patients with severe preeclampsia who develop acute kidney injury. Journal of Clinical Medicine, 10(23), 5629.

Ruiz-Minaya, M., Mendizabal-Vicente, E., Vasquez-Jimenez, W., Perez-Burrel, L., Aracil-Moreno, I., Agra-Pujol, C., Bernal-Claverol, M., Martínez-Bernal, B. L., Muñoz-Fernández, M., Morote-Gonzalez, M., Ortega, M. A., Lizarraga-Bonelli, S., & De Leon-Luis, J. A. (2022). Retrospective analysis of patients with gynaecological uterine sarcomas in a tertiary centre. Journal of Personalized Medicine, 12(2), 222.

Yajie Liu | Cardiac Imaging | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Yajie Liu | Cardiac Imaging | Best Researcher Award

Peking University Shenzhen Hospital | China

Author Profile:

Scopus

Orcid

🌟Prof. Dr. Yajie Liu – A Pioneer in Radiation Oncology & Cancer Research Excellence

🎓 EARLY ACADEMIC PURSUITS

Dr. Yajie Liu began her medical journey with a Bachelor of Medicine (1985–1990) from Norman Bethune University of Medical Sciences. Driven by a deep interest in oncology, she completed her Master's degree in Oncology (1993–1996) from Harbin Medical University, followed by a prestigious Ph.D. in Oncology (1998–2001) at the Peking Union Medical College.

To expand her global medical perspective, she completed a Visiting Scholar Fellowship in Radiation Oncology at Chonnam National University Hospital in South Korea in 2010.

🏥 PROFESSIONAL ENDEAVORS

Dr. Liu's medical career spans over three decades of dedicated clinical service and leadership:

  • 1990–1992: Resident Physician, ENT, First Workers' Hospital of Liaohe Petroleum Exploration Bureau

  • 1992–1998: Resident & Attending Physician, Radiation Oncology, The Third Affiliated Hospital of Harbin Medical University

  • 2001–2017: Progressed from Attending to Chief Physician and Deputy Director at Shenzhen People’s Hospital

  • 2017–Present: Chief Physician and Director, Department of Radiation Oncology, Peking University Shenzhen Hospital

Her ascent to leadership reflects a consistent trajectory of clinical excellence and patient-centered care in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC IMAGING

Dr. Liu has led and co-led numerous research projects focused on:

  • Radiosensitization in Cancer Therapy

  • Hyperthermia and Serum Biomarkers

  • Radiation-Induced Brain Injury

  • Gene Assays for Breast Cancer Prognosis

  • Advanced Radiotherapy Strategies for Rectal and Colorectal Cancer

She has actively participated in national-level research, contributing to the Ministry of Science & Technology's high-impact projects on biomarkers and innovative radiotherapy techniques.

💡 RESEARCH FUNDING & PROJECT LEADERSHIP

As Principal Investigator (PI):

  • Shenzhen Science & Technology Bureau (4 Projects)

  • Shenzhen Health Commission (1 Project)

  • International Collaboration Grant (¥500K)

These funded projects demonstrate her innovative approach in blending clinical insight with technological advancement, especially in plasma therapy and hypoxic tumor sensitization.

🌐 PROFESSIONAL LEADERSHIP & ACADEMIC SERVICE

Dr. Liu holds key roles in multiple national and regional medical bodies:

  • Standing Committee Member, CRTOG

  • Committee Member, Radiotherapy Branch, Chinese Medical Doctor Association

  • Vice Chair, Lung Cancer Committee, Guangdong Women Doctors’ Association

  • Director, Radiotherapy Branch, Shenzhen Anti-Cancer Association

  • Council Member, Jiusan Society Shenzhen Chapter

Her positions reflect widespread recognition of her expertise and leadership in oncology.

📚 ACADEMIC CITES & COLLABORATIONS

While specific citation metrics are not provided here, Dr. Liu’s work on biomarkers, 21-gene assays, radiation injury, and colorectal cancer radiosensitization has contributed to national and international collaborations, significantly enriching the literature in radiation oncology.

🌍 IMPACT AND INFLUENCE

Dr. Liu's multidisciplinary research has influenced clinical protocols, improved patient outcomes, and inspired young oncologists across China. Her work on low-temperature plasma in radiosensitization reflects her commitment to cutting-edge translational oncology.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yajie Liu's legacy is marked by:

  • Pioneering radiotherapy techniques

  • Mentoring future oncology leaders

  • Driving forward international research collaborations

Her future direction is expected to focus on precision oncology, AI-guided radiotherapy planning, and expanding patient-centered cancer care models.

📑 NOTABLE PUBLICATIONS

"Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress"

Authors: M Yang, D Shi, J Lyu, Y Pan, Y Lyv, X Chen, Y Ouyang, Y Liu, Y Li, L Song
Journal: Redox Biology
Year: 2025

"X-ray-activated nanoscintillators integrated with tumor-associated neutrophils polarization for improved radiotherapy in metastatic colorectal cancer"

Authors: H Li, J Zeng, Q You, M Zhang, Y Shi, X Yang, W Gu, Y Liu, N Hu, Y Wang, X Chen, J Mu
Journal: Biomaterials
Year: 2025

Yaodong Li | Electrophysiology | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Yaodong Li | Electrophysiology | Best Researcher Award

Prof. Yaodong Li, Department of Pacing and Electrophysiology, the First Affiliated Hospital of Xinjiang Medical University, China

Prof. Yaodong Li is a leading expert in cardiac electrophysiology at the First Affiliated Hospital of Xinjiang Medical University, China. He holds a Doctor of Medicine in Cardiology from Xinjiang Medical University and serves as Professor and Chief Physician at the Cardiovascular Disease Center. Renowned for his work in pacing and atrial fibrillation, he has received numerous national and regional awards for scientific and clinical innovation. With several projects funded by the National Natural Science Foundation of China, Prof. Li is recognized as a “Research-oriented Talent” and continues to advance cardiovascular medicine through research, clinical excellence, and education.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Yaodong Li embarked on his medical journey at Xinjiang Medical University, where he pursued a Doctor of Medicine in Cardiology from September 2008 to July 2012 in Urumqi, Xinjiang. His foundational years in this esteemed institution laid the groundwork for a career deeply rooted in cardiovascular research and clinical excellence. During his academic training, he quickly distinguished himself through rigorous study and early contributions to scientific research.

📚 PROFESSIONAL ENDEAVORS:

Since August 2018, Prof. Li has served as a Professor and Chief Physician at the Cardiovascular Disease Center of Xinjiang Medical University. His professional journey reflects an upward trajectory marked by commitment to patient care, cutting-edge electrophysiological techniques, and leadership in academic medicine.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ELECTROPHYSIOLOGY:

Prof. Li’s core expertise lies in cardiac electrophysiology, pacing, and atrial fibrillation management. He has been actively involved in national and regional scientific research projects, showcasing a strong focus on innovative treatment modalities and clinical electrophysiological advancements. His research is widely respected for its clinical relevance and technical innovation.

🏆 IMPACT AND INFLUENCE:

Prof. Li’s work has earned him numerous awards and honors, demonstrating his prominence within the national and regional cardiology communities:

  • 2008–2023: Multiple Scientific and Technological Progress Awards from Urumqi City and Xinjiang Autonomous Region

  • 2012: Awarded for Excellent Paper at the 10th National Academic Biannual Meeting of the Chinese Society of Electrophysiology and Pacing

  • 2013 & 2014: Second Prize at the Xinjiang Natural Science Awards (Ranked 2nd)

  • 2022: Recognized with the “Elite in Atrial Fibrillation Prevention and Treatment” Clinical Technology Innovation Honor

  • 2023: Swept honors at the 14th Pacing Summit Forum including:

    • First Prize for Excellent ICD Case

    • Second Prize for Leadless Excellent Case

    • Excellent Young Physician Award

🔎 ACADEMIC CITES AND RECOGNITION:

His studies have contributed significantly to Chinese cardiovascular literature, often cited in national medical conferences and publications. His rankings in award listings reflect not only quality research but also peer acknowledgment of his impact on clinical practice and knowledge dissemination.

🌟 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Yaodong Li represents the future of electrophysiology in China—a visionary in device therapy, pacing technologies, and clinical research leadership. As a “Research-oriented Talent” honored by the Chinese Research Hospital Association in 2024, he is set to:

  • Inspire a new generation of electrophysiologists

  • Spearhead multicenter research projects on atrial fibrillation and ICD innovations

  • Promote global collaborations in cardiac rhythm management

🌍CONCLUSION:

Prof. Yaodong Li stands as a distinguished figure in the field of cardiac electrophysiology, blending clinical expertise with groundbreaking research and innovation. His dedication to advancing pacing techniques and atrial fibrillation treatment has earned him national recognition, prestigious awards, and significant research funding. As a mentor, physician, and scientist, he continues to shape the future of cardiovascular care in China and beyond. With a passion for excellence and a commitment to improving patient outcomes, Prof. Li remains a true pioneer and inspiration in the world of cardiology.

TOP NOTABLE PUBLICATIONS

Title: MAPK14/AIFM2 pathway regulates mitophagy-dependent apoptosis to improve atrial fibrillation
Authors: Wang, Lu; Sang, Wanyue; Jian, Yi; …; Tang, Baopeng; Li, Yaodong
Journal: Journal of Molecular and Cellular Cardiology
Year: 2025

Title: The impact of frailty on the prognosis of chronic heart failure patients treated with cardiac resynchronization therapy defibrillator implantation
Authors: Gao, Liang; Lyu, Huasheng; Tang, Baopeng; …; Zukela, Tuerhong; Lu, Yanmei
Journal: Zhonghua Nei Ke Za Zhi (Chinese Journal of Internal Medicine)
Year: 2025

Title: Effect of renal denervation on atrial neural and structural remodeling in rats with obesity-related atrial fibrillation and its mechanism
Authors: Jian, Yi; Sang, Wanyue; Wang, Lu; …; Zhang, Xing; Li, Yaodong
Journal: Chinese Journal of Pathophysiology
Year: 2024

Title: Safety and efficacy of cardioneuroablation for vagal bradycardia in a single arm prospective study
Authors: Han, Yafan; Shao, Mingliang; Yang, Hang; …; Tang, Baopeng; Li, Yaodong
Journal: Scientific Reports
Year: 2024

Title: A case of endocardial dissection caused by Micra implantation
Authors: Zhang, Jianghua; Shang, Shuai; Dong, Zhenyu; …; Xiaokereti, Jiasuoer; Tang, Baopeng
Journal: BMC Cardiovascular Disorders
Year: 2024

Title: Strategy Optimization for a Combined Procedure in Patients With Atrial Fibrillation: The COMBINATION Randomized Clinical Trial
Authors: Du, Xianfeng; Chu, Huimin; Yang, Bing; …; Yu, Xinzhi; Chen, Xiaomin
Journal: JAMA Network Open
Year: 2024

Title: CALCOCO2 prevents AngII-induced atrial remodeling by regulating the interaction between mitophagy and mitochondrial stress
Authors: Sang, Wanyue; Yan, Xiaoji; Wang, Lu; …; Tang, Baopeng; Li, Yaodong
Journal: International Immunopharmacology
Year: 2024

Xianhong Ou | Cardiovascular Pharmacology | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Xianhong Ou | Cardiovascular Pharmacology | Best Researcher Award

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012